Navigation Links
BMP Sunstone Acquires 'Runchang Capsule' and Related LFHC Technology
Date:11/20/2008

PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company") today announced that its wholly-owned subsidiary, Sunstone (Tangshan) Pharmaceutical Co., Ltd ("Sunstone"), has signed an agreement to acquire "Runchang capsule," a liquid- filled hard capsule (LFHC) used to treat constipation. Sunstone will also receive the entire LFHC filling and sealing production line, as well as related LFHC technology from Darentang Pharmaceutical, which is a subsidiary of Tianjin Zhongxin Pharmaceutical Group Corporation Limited (SSE: 600329; SGX: TIAN). Upon completion of the transaction, BMP Sunstone will become the only current manufacturer of LFHC capsules in China. The Company plans to start promoting the Runchang capsule in the Chinese market in late 2009.

Zhiqiang Han, President and Chief Operating Officer of BMP Sunstone, commented, "The Runchang capsule is a natural plant-based medicine for the treatment of constipation. Compared with competing products on the market, the capsule specifically delivers the medicine to the colon area through its unique LFHC formulation. In addition, the Runchang capsule fits well into our current therapeutic focus in women's health, as women make up the majority of the demand in constipation market."

David Gao, Chief Executive Officer of BMP Sunstone, concluded, "Besides acquiring an approved product, the acquisition will afford us the sole proprietary ownership of LFHC technology in China. We plan to further utilize the targeted-release technology to our existing products to enhance our competitive position and, ultimately, our market share. We intend to fully leverage our existing channels and sales platform to capitalize on the market demand for constipation products, especially within the areas of women's and children's health."

Mr. Han continued, "As living standards have improved in China, the dietary structure and lifestyles have also evolved and fiber content in the diet has been increasingly replaced by protein. As a result, the incidence of constipation has surged and in 2008, we believe the constipation market in China has grown to more than 7 billion RMB with an annual growth rate of 9%- 10% and approximately 6% of Chinese people, of which 80% are women, suffer from varying degrees of constipation. As a dedicated provider of women's and children's health, Sunstone has successfully established three national brands: Confort (for the treatment of female genital tract infection); Nemei (for the treatment of other female diseases); and Goodbaby (for the treatment of pediatric diseases). The Runchang capsule can utilize our existing channels for women's branded products. We believe the Runchang capsule provides us with a good opportunity to extend our brands and product portfolio."

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Currently this portfolio includes eight products under exclusive multi-year licenses for China, primarily focused on women's health and pediatrics. The Company also owns Sunstone Pharmaceutical Co. Ltd., which manufactures leading pediatric and women's health products, including two of China's most recognized brands, "Hao Wawa" and "Confort," sold through approximately 50,000 pharmacies in China. The Company also provides pharmaceutical distribution services through its subsidiaries in Beijing and Shanghai, and through its affiliate, Guangzhou Pharmaceuticals Corp. The Company has its main office in Beijing, with a US office in Plymouth Meeting, PA. For more information, please visit http://www.bmpsunstone.com .

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about the timing of the completion and terms of the proposed acquisition of the assets related to the Runchang capsule, the timing of the Company's promotion of the Runchang capsule in the Chinese market, the market demand for the Runchang capsule and the ability of the Company to leverage our existing channels and sales platform to capitalize on the market demand for constipation products. These statements are subject to uncertainties and risks including, but not limited to, negotiating definitive terms and definitive agreements regarding the proposed acquisition, satisfying the conditions in such definitive agreements, regulatory review, sales and marketing, operating performance, general financial, economic, and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, the ability to timely manufacture and distribute the Runchang capsule and other risks contained in reports filed by the Company with the Securities and Exchange Commission. In addition, the Company disclaims any obligation to update any forward- looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
2. BMP Sunstone Receives Import Drug License (IDL) from SFDA
3. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
4. BMP Sunstone Reports Second Quarter 2008 Financial Results
5. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
6. BMP Sunstone Announces Participation in September Investor Conference
7. BMP Sunstone Announces Participation in November Investor Conferences
8. BMP Sunstone Reports Third Quarter 2008 Financial Results
9. BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesdays Call
10. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
11. Neogen Acquires Kane Enterprises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Premier executive ... & Life Science Search Firm by Hunt Scanlon Media. , Hunt Scanlon ... and the most widely referenced global news source in the human capital sector. , ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced ... to be held on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. ... Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):